Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13615-13623

  Morote, Juan ^a,c   Celma, Anna ^a   Planas, Jacques ^a   Placer, José ^a   de Torres, Inés ^a   Olivan, Mireia ^c   Carles, Juan ^b,d   Reventós, Jaume ^c,d,e   Doll, Andreas ^c,d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^e BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Cholesterol; Prostate cancer aggressiveness; Prostate cancer risk; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; BLOOD; CANCER STAGING; CARDIOVASCULAR DISEASES; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RISK; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84924318898     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813615     Document Type: Article

References (29)

1. Jemal, A.; Bray, F.; Center, M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Bay, F.; Lortet-Tieulent, J.; Ferlay, J.; Forman, D.; Auvinen, A. Prostate cancer incidence and mortality trends in 37 European countries: An overview. Eur. J. Cancer 2010, 46, 3040-3052.
3. Anand, S.S.; Yusuf, S. Stemming the global tsunami of cardiovascular disease. Lancet 2011, 377, 529-532.
4. Gutt, R.; Tonlaar, N.; Kunnavakkam, R.; Karrison, T.; Weichselbaum, R.; Liauw, S. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol. 2010, 28, 2653-2659.
5. Gonyeau, M.; Yuen, D. A clinical review of statins and cancer: Helpful or harmful? Pharmacotherapy 2010, 30, 177-194.
6. Batty, G.; Kivimaki, M.; Clarke, R.; Smith, G.D.; Shipley, M. Modifiable risk factors for prostate cancer mortality in London: Forty years of follow-up in the Whitehall study. Cancer Causes Control 2011, 22, 311-318.
7. Bravi, F.; Scotti, L.; Bosetti, C.; Talamini, R.; Negri, E.; Montella, M.; Franceschi, S.; la Vecchia, C. Selfreported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann. Oncol. 2006, 17, 1014-1017.
8. Kark, J.; Smith, A.; Hame, G. Serum retinol and the inverse relationship between serum cholesterol and cancer. Br. Med. J. 1982, 284, 152-154.
9. Thompson, M.; Garland, C.; Barrett-Connor, E.; Khaw, K.; Friedlander, N.J.; Wingard, D.L. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am. J. Epidemiol. 1989, 129, 511-517.
10. Hiatt, R.; Fireman, B. Serum cholesterol and the incidence of cancer in a large cohort. J. Chronic Dis. 1986, 39, 861-870.
11. Knekt, P.; Reunanen, A.; Aromaa, A.; Heliovaara, M.; Hakulinen, T.; Hakama, M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J. Clin. Epidemiol. 1988, 41, 519-530.
12. Mondul, A.; Clipp, S.; Helzlsouer, K.; Platz, E. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010, 21, 61-68.
13. Platz, E.A.; Clinton, S.; Giovannucci, E. Association between plasma cholesterol and prostate cancer in the PSA era. Int. J. Cancer 2008, 123, 1693-1698.
14. Platz, E.; Till, C.; Goodman, P.; Goodman, P.J.; Parnes, H.L.; Figg, W.D.; Albanes, D.; Neuhouser, M.L.; Klein, E.A.; Thompson, I.M., Jr.; et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2807-1213.
15. Kok, D.E.G.; van Roermund, J.G.H.; Aben, K.K.H.; den Heijer, M.; Swinkels, D.W.; Kampman, E.; Kiemeney, L.A.L.M. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis. 2011, 14, 340-345.
16. Shafique, K.; McLoone, P.; Qureshi, K.; Hart, C.; Morrison, D. Cholesterol and the risk of grade-specific prostate-cancer incidence: Evidence from two large prospective cohort studies with up to 37 years follow up. BMC Cancer 2012, 12, 25.
17. Demierre, M.; Higgins, P.; Gruber, S.; Hawk, E.; Lippman, S. Statins and cancer prevention. Nat. Rev. Cancer 2005, 5, 930-942.
18. Bensal, D.; Undela, K.; D'Cruz, S.; Shifano, F. Statin use and risk of prostate cancer: A meta-analysis of observational studies. PLoS One 2012, 7, e46691.
19. Boudreau, D.; Yu, O.; Buist, D.; Miglioretti, D. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008, 19, 767-774.
20. Farwell, W.; Scranton, R.; Lawler, E.; Lew, R.A.; Brophy, M.T.; Fiore, L.D.; Gaziano, J.M. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 2008, 100, 134-139.
21. Hamilton, R.; Goldberg, K.; Platz, E.; Freedland, S. The influence of statin medications on prostate-specific antigen levels. J. Natl. Cancer Inst. 2008, 100, 1511-1518.
22. Friedman, G.; Flick, E.; Udaltsova, N.; Chan, J.; Quesenberry, C.; Habel, L. Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol. Drug Saf. 2008, 17, 27-36.
23. Bonovas, S.; Filioussi, K.; Sitaras, N. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer 2008, 123, 899-904.
24. Jacobs, E.; Rodriguez, C.; Bain, E.; Wang, Y.; Thun, M.; Calle, E. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2213-2217.
25. Murtola, T.; Tammela, T.; Lahtela, J.; Auvinen, A. Cholesterol-lowering drugs and prostate cancer risk: A population-based casecontrol study. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2226-2232.
26. Murtola, T.J.; Tammela, T.L.J.; Määttänen, L.; Huhtala, H.; Platz, E.A.; Ala-Opas, M.; Stenman, U.-H.; Auvinen, A. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int. J. Cancer 2010, 127, 1650-1659.
27. Mondul, A.; Weinstein, S.J.; Virtamo, J.; Albanes, D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011, 22, 1545-1552.
28. Roy, M.; Kung, H.; Ghosh, P. Statins and prostate cancer: Role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am. J. Cancer Res. 2011, 1, 542-561.
29. Remzi, M.; Fong, Y.; Dobrovits, M.; Anagnostou, T.; Seitz, C.; Waldert, M.; Harik, M.; Marihart, S.; Marberger, M.; Djavan, B. The Vienna nomogram: Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J. Urol. 2005, 174, 1256-1260.